Skip to main content
Premium Trial:

Request an Annual Quote

James Burns, J. Stark Thompson

Premium

James Burns, president and CEO of the clinical-stage pharmaceutical company EntreMed, has joined Ciphergen's board of directors, Ciphergen announced last week.

Burns joined EntreMed in June 2004. Prior to that, he was the co-founder of MedPointe, where he served as president and executive vice president. From 2000 to 2001, Burns served as founder and managing director of MedPointe Captial Partners. From 1993 to 1999, Burns was the founder, chairman, president and CEO of the biotechnology company Osiris Therapeutics. From 1986 to 1992, he was vice chairman of Health Care Investment, and a founding general partner of Healthcare Ventures, a venture capital partnership that specialized in forming companies built around new pharmaceutical and biotechnology products. From 1981 to 1986, Burns served as group president and vice president of the laboratory products group at Becton Dickinson.

Burns is the chairman of the executive committee of the International BioResources Group and the American Type Culture Collection, and a trustee of the University of Maryland Biotechnology Institute. He earned his BS and MS degrees in biological sciences from the University of Illinois. In addition, he received an MBA degree from DePaul University.


Luminex this week announced the appointment of J. Stark Thompson to the board of directors, where he will serve as a class III director. Most recently, Thompson served as president, CEO, and director of Life Technologies. Thompson has a BS from Muskingum College and an MS and PhD in Physiological Chemistry from Ohio State University. He currently serves as chair of the board of directors of Gene Logic, as well as serving as a director in various other private and civic organizations.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.